Luigi Portella

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" — Italy

Medicine · Health Sciences

22h-index1.6kcitations133works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(57), Cancer Immunotherapy and Biomarkers(32), Chemokine receptors and signaling(32), Renal cell carcinoma treatment(18), Immunotherapy and Immune Responses(18)

Publications133 total

Abstract 676: First in man microdose trial of [68Ga]Ga-R54, CXCR4 targeted PET tracer: Comparison with [18F]-FDG and proof of concept in lung cancer models
Cancer Research·2025
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells
PLoS ONE·2024· 1 citedOpen Access
Supplementary Figure S11 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S7 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S6 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S9 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Tables S1-S12 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S5 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S1 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S10 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S8 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S2 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S3 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Data from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S4 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
Supplementary Figure S13 from <sup>KIR2DL2/DL3+</sup>NKs and <sup>Helios+</sup>Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
2024Open Access
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer
Clinical Cancer Research·2024· 3 citedOpen Access
CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization
Heliyon·2024· 5 citedOpen Access
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients
British Journal of Cancer·2024· 14 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Stefania Scala(38), Crescenzo D’Alterio(27), Maria Napolitano(23), Anna Maria Trotta(20), Caterina Ieranò(19), Giuseppina Rea(12), David M. Nanus(11), Paraskevi Giannakakou(11), Sandro Pignata(10), Antônio Barbieri(9), Antonio Luciano(9), Fabiana Tatangelo(9), Sara Santagata(9), Daniel Worroll(8), Giosuè Scognamiglio(8), Claudio Arra(8), Salvatore Di Maro(8), Scott T. Tagawa(7), Brian J. Kirby(7), Giuseppe Castello(7)